Abstract
Purpose: The aim of the present work was to evaluate novel series of 6-substituted benzimidazole-2- carbamates for antitumor activity. Method/approach: Evaluation of antitumor activity was carried out in vitro in human malignant cell lines A549 (lung), SK-MEL-2 (melanoma), COLO 205(colon) and JURKAT (leukemia) by sulforhodamine (SRB) assay. The test compounds were compared with adriamycin (doxorubicin) as positive control for antitumor activity. Findings: Significant activity against cell proliferation was demonstrated by the test compounds in in vitro cytotoxicity assays. Application: The findings of the study can be used to develop novel 6-substituted benzimidazole-2-carbamates as potent antitumor agents. Social value: As cancer is still a dreaded disease, the present work provides scope for introduction of a new molecule belonging to benzimidazole class of compounds for treatment of cancer having broad spectrum of activity and minimal side effects. Research Value: The series of novel 6-substituted benzimidazole-2-carbamates can be structurally optimized further to yield a compound with remarkable in vitro and in vivo antitumor properties which can then be translated in to clinic if found to exhibit minimum toxicity. Conclusion: It can be concluded that all the compounds tested showed potent in vitro antitumor activity in cell lines tested.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
